Fetus

• The complaint seeks a judicial declaration, on an expedited basis, that DSE is contractually required to make a $300 million milestone payment to Esperion upon regulatory approval.
• “This amended complaint, filed by Gibson Dunn and supported by new evidence, makes clear that we are entitled to the $300 million milestone payment from DSE upon regulatory approval.
• We will not acquiesce to DSE’s commercially dishonest tactics,” says Esperion President and Chief Executive Officer Sheldon Koenig.
• “We are working diligently to resolve this dispute as we continue to commercialize bempedoic acid in Europe and around the world.

• When colds, flus and allergies hit, many people automatically turn to over-the-counter medications to push through and treat their symptoms.
• Nearly 70% of adults in the U.S. use over-the-counter medications as a first-line response for treating cold and flu symptoms.
• We are a pharmacoepidemiologist and pharmacist team and we investigate adherence to medications and potential harms of medications associated with drug-drug interactions.
• Another study estimated that every year, 26,735 people went to the emergency room for adverse events related to over-the-counter cold and cough medications.

The dangers of mixing medications

• Pharmacists and physicians are typically knowledgeable about potential drug interactions, so it is very important for patients to ask their health care providers which over-the-counter medications are safe for them to use.
• It is important to read the package ingredients of over-the-counter medications closely to avoid duplication of doses.
• Cold medications are typically made up of multiple ingredients, including pain relievers, nasal decongestants and cough suppressants or expectorants.
• Combining these decongestants with monoaminooxidase inhibitors or tricyclic antidepressants could lead to very high blood pressure and heart rhythm problems.

Each person responds to drugs differently

• As we age, our bodies begin to lose the ability to efficiently clear drugs, which increases the risk of adverse events and unintentional overdoses.
• Some drugs can be dangerous for people who have particular health conditions.
• In addition, since these drugs are associated with increased blood pressure, patients with hypertension, hyperthyroidism or heart disease should be careful when using them, or avoid them altogether.

Alternatives for children

• The Food and Drug Administration and the Centers for Disease Control and Prevention do not recommend giving cold medications to children under age 4.
• Because of a variety of factors, young children have a higher risk of accidental overdose and adverse events that could lead to death.
• Research has shown that honey can be helpful for reducing cold and flu symptoms in children older than age 1.

Pregnancy best practices

• Acetaminophen is the doctor-recommended over-the-counter medication for management of pain and fever at any stage of pregnancy.
• Any other pain relievers or anti-inflammatory medicine such as ibuprofen, ketoprofen, naproxen and aspirin should not be taken during pregnancy without a doctor’s approval.
• For symptoms such as nasal congestion during pregnancy, a decongestant called oxymetazoline in its intranasal form is the drug of choice.

• NEW YORK, April 11, 2023 (GLOBE NEWSWIRE) -- Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (“Calliditas”), announced the publication of a cost-effective analysis of Nefecon (marketed in the United States as TARPEYO® (budesonide) delayed release capsules) versus standard of care (SOC) for people with Primary IgA Nephropathy (IgAN) in the United States (US).
• Health-state occupancy probabilities and key model inputs were based on the individual patient-level data from NefIgArd, the Phase 3 randomized controlled trial evaluating Nefecon.
• Andrew Udell, president, North America at Calliditas stated: “These findings are timely and relevant in light of the 2-year eGFR results from the NefIgArd trial we recently announced.
• Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory clinical trial.

• NIJMEGEN, Netherlands, April 12, 2023 /PRNewswire/ -- Byondis B.V., an independent, clinical-stage Dutch biopharmaceutical company creating precision medicines, today announced that Molecular Cancer Therapeutics (an American Association for Cancer Research journal) has published encouraging preclinical data on its investigational, next generation antibody-drug conjugate (ADC) BYON3521.
• The article, "Preclinical profile of BYON3521 predicts an effective and safe c-MET-antibody-drug conjugate," suggests that BYON3521 has an encouraging safety/efficacy window with potential for clinical benefit in patients.
• The data from in vitro and in vivo studies showed that BYON3521 potently and selectively kills tumor cells expressing c-MET, even at low c-MET-expressing levels.
• The antibody part of BYON3521 binds to c-MET on the surface of the cancer cell and the ADC is internalized.